Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: 18F Fluoroestradiol Radiopharmaceutical with PET/CT
Sponsor: Zionexa
Collaborators: GE Healthcare|Simbec-Orion Group|Keosys